These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 22058172

  • 1. Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
    Nainani N, Patel N, Tahir N, Kumar R, Weber-Shrikant E, Gundroo AA, Murray BM, Tornatore KM, Blessios GA, Venuto RC.
    Nephrol Dial Transplant; 2012 May; 27(5):2077-83. PubMed ID: 22058172
    [Abstract] [Full Text] [Related]

  • 2. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B.
    Transplantation; 2001 May 15; 71(9):1282-7. PubMed ID: 11397963
    [Abstract] [Full Text] [Related]

  • 3. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF, Mahmoud KM, Ismail AM, Sheashaa HA, Kamal AI, Ghoneim MA.
    Exp Clin Transplant; 2011 Oct 15; 9(5):295-301. PubMed ID: 21967254
    [Abstract] [Full Text] [Related]

  • 4. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB, Foster KW, Miles CD, Kalil AC, Florescu DF, Sandoz JP, Rigley TH, Malik T, Wrenshall LE.
    PLoS One; 2015 Oct 15; 10(10):e0139247. PubMed ID: 26465152
    [Abstract] [Full Text] [Related]

  • 5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 15; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 6. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B, Zhang S, MacConmara M, Gao A, Sandikci B, Ayvaci MU, Mete M, Tsapepas D, Rajora N, Mohan P, Lakhia R, Lu CY, Vazquez M.
    Clin J Am Soc Nephrol; 2015 Jun 05; 10(6):1041-9. PubMed ID: 25979971
    [Abstract] [Full Text] [Related]

  • 7. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
    Heilman RL, Khamash HA, Smith ML, Chakkera HA, Moss AA, Reddy KS.
    Clin Transplant; 2013 Jun 05; 27(5):772-80. PubMed ID: 23924146
    [Abstract] [Full Text] [Related]

  • 8. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B, Tönshoff B.
    Paediatr Drugs; 2011 Feb 01; 13(1):49-69. PubMed ID: 21162600
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J.
    Transplantation; 2005 Aug 27; 80(4):457-65. PubMed ID: 16123718
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 27; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 11. The utility of 6-month protocol renal biopsy under modern immunosuppression.
    Yango A, Gohh R, Wang LJ, Morrissey P, Shih M, Lowery K, Charpentier K, Gautam A, Mendonca C, Kumar S, Dworkin L, Monaco A.
    Clin Nephrol; 2008 Dec 27; 70(6):490-5. PubMed ID: 19049705
    [Abstract] [Full Text] [Related]

  • 12. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
    Welberry Smith MP, Cherukuri A, Newstead CG, Lewington AJ, Ahmad N, Menon K, Pollard SG, Prasad P, Tibble S, Giddings E, Baker RJ.
    Transplantation; 2013 Dec 27; 96(12):1082-8. PubMed ID: 24056618
    [Abstract] [Full Text] [Related]

  • 13. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G, Murer L, Ghio L, Pietrobon B, Ginevri F, Ferraresso M, Cardillo M, Scalamogna M, Perfumo F, Edefonti A, Zanon GF, Zacchello G.
    Transpl Int; 2005 Jan 27; 18(1):36-42. PubMed ID: 15612981
    [Abstract] [Full Text] [Related]

  • 14. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE, Gohh R, Shaffer D, Crosson A, Madras PN, Sahyoun AI, Monaco AP.
    Transplantation; 1997 Mar 27; 63(6):845-8. PubMed ID: 9089224
    [Abstract] [Full Text] [Related]

  • 15. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 16. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM, Kobashigawa J, Klintmalm G.
    Clin Transplant; 2008 Nov 15; 22(1):1-15. PubMed ID: 18217899
    [Abstract] [Full Text] [Related]

  • 17. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F, Oettl T, Descoeudres B, Bachmann A, Guerke L, Mihatsch MJ, Dickenmann M, Steiger J.
    Transplant Proc; 2012 Dec 15; 44(10):2961-5. PubMed ID: 23195006
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK, Klinger M, Vítko Š, Glyda M, Midtvedt K, Stefoni S, Citterio F, Pietruck F, Squifflet JP, Segoloni G, Krüger B, Sperschneider H, Banas B, Bäckman L, Weber M, Carmellini M, Perner F, Claesson K, Marcinkowski W, Ostrowski M, Senatorski G, Nordström J, Salmela K.
    Transplantation; 2012 Sep 15; 94(5):492-8. PubMed ID: 22858806
    [Abstract] [Full Text] [Related]

  • 19. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
    Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R.
    Liver Transpl; 2000 Nov 15; 6(6):734-40. PubMed ID: 11084060
    [Abstract] [Full Text] [Related]

  • 20. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ.
    Clin Transplant; 2007 Nov 15; 21(1):101-9. PubMed ID: 17302598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.